why choose us

Clinical Trials Search

Showing 11,730 of 132,366 result(s)
Effectiveness and Use of COVID-19 Vaccines Using Information From the California State Vaccine Registry

Status: Completed

Condition: SARS-CoV-2

Interventions: Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4;BA.5) is FDA authorized under Emergency Use Authorization (EUA) for active

Date: 2023-05-23

Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery

Status: Completed

Condition: Sugammadex

Interventions: Quantitative electromyographic (EMG) monitoring

Date: 2023-05-23

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

Status: Completed

Condition: Dedifferentiated Liposarcoma

Interventions: Will be administered PO daily for 24 weeks

Date: 2023-05-23

ASK-PrEP (Assistance Services Knowledge-PrEP)

Status: Completed

Condition: Substance Use Disorders

Interventions: Using a client-centered approach, the PrEP navigator works to link participants into SUD treatment and other ancillary behavioral health and support s

Date: 2023-05-23

Promoting Math in Young Children: Leveraging Pediatric Clinics to Reach Underrepresented Children in Rural Communities

Status: Completed

Condition: Early Math Learning

Interventions: Texts sent to caregivers meant to increase parent child interaction around math and literacy, sent to participants 4x a week for 8 months

Date: 2023-05-23

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Status: Completed

Condition: Metastatic Castrate-sensitive Prostate Cancer

Interventions: Apalutamide will be administered orally from Day 1 of Cycle 1 till 6 months in initial treatment phase and then in main treatment phase from Day 1 of

Date: 2023-05-23

Timing of Active Void Trials After Urogynecologic Procedures

Status: Completed

Condition: Postoperative Care

Interventions: Patients will be given up to 30 minutes to void.

Date: 2023-05-22

M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Status: Completed

Condition: Non-Small Cell Lung Cancer

Interventions: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other

Date: 2023-05-22

Reshaping Postpartum Follow-up

Status: Completed

Condition: Hypertension in Pregnancy

Interventions: The intervention will consist of a card given to patients at time of discharge.
One side of the card will list the patient's name and a list

Date: 2023-05-22